Specifically, we investigated whether (1) NGS of Ig LC rearrangements only in cfDNA and (2) magnetic enrichment of CD138-positive (CD138+) cells before MFC measurement (me-MFC) enables reliable quantification of disease burden in both serologically detectable and undetectable MM. This evidence concerns the gene SDC1 and Miyoshi myopathy.